Novocure (NVCR) | Stock Overview & Key Data
Novocure Performance Comparison
Stock Range
Today's Range
Low: $11.11
High: $11.69
on August 8, 2025
52 Week Range
Low: $10.91
High: $34.13
on July 30, 2025
on December 18, 2024
All-Time High: $232.76 on June 21, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.3B
EPS
-1.56
P/E Ratio (TTM)
-7.33
Forward P/E
-7.84
P/B Ratio
3.76
PEG Ratio
-7.84
Div. Yield
N/A
ROE
-48.07%
Beta
0.608
Debt to Equity
200.39
Financial Highlights
Profitability
Gross Margin
73.88%
Operating Margin
-24.89%
Profit Margin
-27.13%
Returns and Earnings
Return on Assets (TTM)
-8.64%
Return on Equity (TTM)
-48.07%
EBITDA
$-158.9M
Net Income (TTM)
$-171.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$5.81
Quarterly Revenue Growth (YoY)
5.60%
Quarterly Earnings Growth (YoY)
5.62%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Novocure NVCR | 1.31B Small-cap | -1.68% | -36.44% | -36.18% | -48.59% | -62.89% | -40.45% | -87.05% | -85.30% |
| Abbott Laboratories ABT | 227.88B Mega-cap | 5.50% | 0.70% | 0.22% | 2.27% | 18.38% | 23.52% | 20.45% | 34.29% |
| Boston Scientific BSX | 152.55B Large-cap | -2.15% | 0.71% | -0.15% | -2.86% | 15.39% | 35.39% | 143.68% | 163.41% |
| UFP Technologies UFPT | 1.74B Small-cap | -9.27% | -15.45% | -12.12% | -21.53% | -16.52% | -33.57% | 116.38% | 370.60% |
| Conmed CNMD | 1.58B Small-cap | 4.55% | 4.23% | -5.33% | -18.79% | -18.83% | -18.50% | -47.01% | -35.81% |
| QuidelOrtho QDEL | 1.60B Small-cap | 4.82% | -22.42% | -34.42% | -44.25% | -46.91% | -42.55% | -71.57% | -90.28% |
Ownership & Short Interest
Insider Ownership
9.81%
Institutional Ownership
78.99%
Shares Short
5M
Short Ratio
3.87
Short % of Shares Outstanding
6.96%
Average 10-Day Volume
3M
Average 90-Day Volume
2M
Novocure Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Novocure would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NVCR's 52-week high and low?
- In the last 52 weeks, Novocure reached a high of $34.13 (on December 18, 2024) and a low of $10.91 (on July 30, 2025).
- What is the market cap and P/E ratio for NVCR?
- Curious about Novocure's size and valuation? Its market capitalization stands at 1.31B. When it comes to valuation, the P/E ratio (trailing twelve months) is -7.33, and the forward P/E (looking ahead) is -7.84.
- Does NVCR pay dividends? If so, what's the yield?
- As for dividends, Novocure isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Novocure's main competitors or similar companies to consider before investing?
When looking at Novocure, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT227.88B Healthcare Medical Devices 23.52% 20.45% Boston Scientific
BSX152.55B Healthcare Medical Devices 35.39% 143.68% UFP Technologies
UFPT1.74B Healthcare Medical Devices -33.57% 116.38% Conmed
CNMD1.58B Healthcare Medical Devices -18.50% -47.01% QuidelOrtho
QDEL1.60B Healthcare Medical Devices -42.55% -71.57% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Novocure Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Novocure's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -48.07%, the Debt to Equity ratio from the most recent quarter is 200.39, and its Gross Profit Margin stands at 73.88%.
- What is the recent revenue and earnings growth for NVCR?
- Looking at Novocure's growth, its revenue over the trailing twelve months (TTM) was $630M. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.60%, and quarterly earnings saw a YoY growth of 5.62%.
- How much of NVCR stock is held by insiders and institutions?
- Wondering who owns Novocure stock? Company insiders (like executives and directors) hold about 9.81% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 78.99%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.